Corona .. Sources: The arrival of the drug “Evoshield” to Egypt tomorrow

0
11


01:48 PM

Monday 24 January 2022

Books – Ahmed Gomaa:
Informed sources said that the drug “Evoshield”, produced by the “AstraZeneca” company, is expected to arrive for Corona patients, tomorrow, Tuesday, January 25.

The Consolidated Procurement Authority had contracted with the “AstraZeneca” company, to purchase the drug “EvoShield”, its new formulation, which includes two long-acting antibodies, for the benefit of the Ministry of Health and Population.

The drug “EvoShield” is used to provide protection for people at risk who may not acquire an adequate immune response after being vaccinated with the anti-Covid-19 vaccine, and to help prevent the disease from developing into severe cases in the event of infection with the virus.

The sources indicated, in exclusive statements to Masrawy, that 15,000 doses of the drug are scheduled to arrive, representing the first phase of the contract, out of the total 50,000 doses that Egypt contracted with the company.

The sources confirmed that the rest of the contracting stages will arrive gradually and gradually.

The drug recently obtained an emergency use authorization from the US Food and Drug Administration for the purposes of pre-exposure prophylaxis to the Covid-19 virus.

The drug “EvoShield” is used to provide protection for people at risk who may not acquire an adequate immune response after being vaccinated with the anti-Covid-19 vaccine, and to help prevent the disease from developing into severe cases in the event of infection with the virus.

The company confirmed that the new drug will help those who take immunosuppressive drugs to form immune bodies to resist Corona, and it will be an alternative to the vaccine for the groups that receive immunosuppressive drugs, such as those who receive chemotherapy or those who transplant organs.

About 2% of the world’s population faces increased risks as a result of the body’s inability to generate an adequate immune response to vaccination with the COVID-19 vaccine.

This includes patients with leukemia and other types of cancer who receive chemotherapy; dialysis patients; And those who take medications after organ transplants, or who take immunosuppressive drugs for diseases such as multiple sclerosis and rheumatoid arthritis.

And the analyzes of a clinical trial showed that a dose of 600 milligrams of the drug “EvoShield” given through an intramuscular injection is sufficient to reduce the risk of developing the infection to dangerous stages or death (for any cause) by 88%, compared to those with symptoms of Covid-19 three days ago or less and received Mock doses from within the same experiment.

Quantities of the drug will be purchased for the benefit of the Ministry of Health, which will present it in hospitals, as the drug will not be available in public pharmacies.

Read also:
Egypt contracted it.. details of 3 promising drugs to treat people with corona





Source link
https://www.masrawy.com/news/news_egypt/details/2022/1/24/2163625/%D9%83%D9%88%D8%B1%D9%88%D9%86%D8%A7-%D9%85%D8%B5%D8%A7%D8%AF%D8%B1-%D9%88%D8%B5%D9%88%D9%84-%D8%AF%D9%88%D8%A7%D8%A1-%D8%A5%D9%8A%D9%81%D9%88%D8%B4%D9%8A%D9%84%D8%AF-%D8%A5%D9%84%D9%89-%D9%85%D8%B5%D8%B1-%D8%BA%D8%AF-%D8%A7

LEAVE A REPLY

Please enter your comment!
Please enter your name here